Clinical trials: Stage 2 Hypertension
Type 2 Diabetes
A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an ACEI or ARB and an Additional Antihypertensive Medication
The purpose of this study is to learn if BMS-512148 (Dapagliflozin), after 12 weeks, can improve (decrease) blood pressure in patients with type 2 diabetes with uncontrolled hypertension who are on an Angiotensin-converting…
- Trial name
- NCT01195662
- Testing
- Dapagliflozin
- Where
- 298 sites in United States, Australia and 14 more
- Volunteers
- 2,245 people
- Sponsor
- AstraZeneca
Open-Angle Glaucoma, Ocular Hypertension
Safety and Efficacy of a New Ophthalmic Formulation of Bimatoprost in Patients With Open Angle Glaucoma and Ocular Hypertension
This study will evaluate the safety and efficacy of new ophthalmic formulations of bimatoprost in patients with open angle glaucoma and ocular hypertension.
- Trial name
- NCT01157364
- Testing
- bimatoprost 20 µg generation 2, bimatoprost 15 µg generation 2, bimatoprost 10 µg generation 2
- Where
- 57 sites in United States, Australia and 8 more
- Volunteers
- 109 people
- Sponsor
- Allergan
Hypertension in Pregnancy
Chronic Hypertension and Pregnancy 2 (CHAP2) Pilot Project
The CHAP2 study is designed to provide preliminary data for a larger multicenter study to assess whether treatment of stage 1 hypertension (HTN) in pregnancy improves maternal and or neonatal outcomes.
- Trial name
- CHAP2 (NCT05989581)
- Testing
- Labetalol or Nifedipine
- Where
- United States
- Volunteers
- 74 people, healthy volunteers welcome
- Sponsor
- University of Alabama at Birmingham
Glaucoma
Interactive Study to Increase Glaucoma Adherence to Treatment
Study participants who receive the I-SIGHT intervention will have higher rates of glaucoma treatment compliance (e.g., medication-taking and refill compliance, return for clinical follow-up) and more positive eye health outcomes…
- Trial name
- I-SIGHT (NCT00794170)
- Testing
- Telephone and Print based intervention
- Where
- 2 sites in United States
- Volunteers
- 312 people, healthy volunteers welcome
- Sponsor
- Emory University
Chronic Thromboembolic Pulmonary Hypertension, CTEPH
Riociguat in Patients With Operable CTEPH Prior to Pulmonary Endarterectomy (PEA Bridging Study)
This is a randomised, double-blind, placebo-controlled, multicentre, multinational, prospective study in patients with operable chronic thromboembolic pulmonary hypertension (CTEPH) prior to pulmonary endarterectomy (PEA) with…
- Trial name
- NCT03273257
- Testing
- Riociguat, Pulmonary endarterectomy
- Where
- 4 sites in United States, France and 2 more
- Volunteers
- 14 people
- Sponsor
- International CTEPH Association
Pulmonary Arterial Hypertension
Hemodynamic Evaluation of Dose-response and Safety of Dry Powder Inhalation of Treprostinil
Acute and chronic hemodynamic dose-response and safety evaluation of LIQ861 in PAH subjects.
- Trial name
- NCT03884465
- Testing
- Inhaled dry powder treprostinil (LIQ861)
- Where
- 3 sites in France, Germany
- Volunteers
- 15 people
- Sponsor
- Liquidia Technologies, Inc.
Hypertension
Study of Efficacy and Safety of LCZ696/Amlodipine in Grade 1 and 2 Hypertension Patients Uncontrolled by LCZ696 Monotherapy
This CLAZ696B11302 study is composed of two parts; the Core part including double-blind period, and the open-label extension (OLE) part which is an open-label extension of the Core part.
- Trial name
- NCT06236061
- Testing
- LCZ, LCZ/AML 200 mg/2.5 mg, LCZ/AML 200 mg/5 mg
- Where
- 43 sites in Japan
- Volunteers
- 718 people
- Sponsor
- Novartis Pharmaceuticals
Essential Hypertension
Phase 2 Study to Evaluate the Efficacy and Safety of Irbesartan and Amlodipine Combined or Alone in Patients With Essential Hypetension
A Randomized, Double-blind, Multicenter, Factorial Design, Phase II Study to Evaluate the Efficacy and Safety of Irbesartan and Amlodipine Combined or Alone in Patients With Essential Hypertension
- Trial name
- NCT04488978
- Testing
- Irbesartan/Amlodipine
- Where
- South Korea
- Volunteers
- 440 people
- Sponsor
- Handok Inc.
Uncontrolled Hypertension, Resistant Hypertension
A Study to Evaluate the Efficacy and Safety in Participants With Uncontrolled Hypertension on Two or More Medications Including Participants With Resistant Hypertension
This is a Phase II, multicentre, randomised, double-blinded, placebo-controlled, parallel group study to evaluate the safety, and effect of low, middle and high dose of SAL0120 versus placebo, administered once daily (QD) orally…
- Trial name
- NCT07790120
- Testing
- SAL0120
- Where
- China
- Volunteers
- 256 people
- Sponsor
- Shenzhen Salubris Pharmaceuticals Co., Ltd.
Pulmonary Arterial Hypertension
Effect of CS1 in Subjects With Pulmonary Arterial Hypertension
This is a Phase 2, parallel group study to evaluate the safety, tolerability, PK, and exploratory efficacy of 3 doses of CS1 in the treatment of PAH using the CardioMEMS HF System to obtain repeated measurements of PAP and other…
- Trial name
- NCT05224531
- Testing
- CS1 Administration
- Where
- Sweden
- Volunteers
- 25 people
- Sponsor
- Cereno Scientific AB
Menopause, Hypertension
The Effects of Swimming on Elderly Women With Stage-2 Hypertension
Aging is associated with progressive decreases in arterial health and function as well as overall fitness. It is crucial to prevent or reduce the negative effects of aging on the vasculature and fitness components by implementing…
- Trial name
- NCT03546270
- Testing
- Swimming
- Volunteers
- 100 people
- Sponsor
- Pusan National University
Glaucoma, Ocular Hypertension
Safety and Efficacy Study of Catioprost® (Unpreserved Latanoprost 0.005% Emulsion) Compared to Travatan Z® to Treat Glaucoma and Ocular Surface Disease
The purpose of this study is to compare: the effect of Catioprost® and Travatan Z® on the ocular surface disease (OSD) in subjects with glaucoma or ocular hypertension and ocular surface disease.
- Conditions
- Glaucoma, Ocular Hypertension, Ocular Surface Disease
- Trial name
- NCT01254370
- Testing
- Latanoprost, Travatan Z
- Where
- United States
- Volunteers
- 105 people
- Sponsor
- Santen SAS
Liver Cirrhosis
Zibotentan and Dapagliflozin Combination, EvAluated in Liver Cirrhosis (ZEAL Study)
This is a two part Phase IIa/b multicentre, randomised, double-blind, placebo-controlled, parallel group dose-ranging study to assess the efficacy, safety, and tolerability of the combination of zibotentan and dapagliflozin, and…
- Trial name
- ZEAL (NCT05516498)
- Testing
- Part A: zibotentan (dose B) + dapagliflozin, Part B: zibotentan (dose A) + dapagliflozin
- Where
- 50 sites in United States, Australia and 13 more
- Volunteers
- 205 people
- Sponsor
- AstraZeneca